These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 6149804

  • 1. The 12th J. A. F. Stevenson memorial lecture. Aging, Alzheimer's disease, and the cholinergic system.
    McGeer PL.
    Can J Physiol Pharmacol; 1984 Jul; 62(7):741-54. PubMed ID: 6149804
    [Abstract] [Full Text] [Related]

  • 2. [Neurotransmitter anomalies in Alzheimer's disease].
    Berger B.
    Rev Neurol (Paris); 1984 Jul; 140(10):539-52. PubMed ID: 6150545
    [Abstract] [Full Text] [Related]

  • 3. Positron emission tomography and the possible origins of cytopathology in Alzheimer's disease.
    McGeer PL, McGeer EG, Kamo H, Wong K.
    Prog Neuropsychopharmacol Biol Psychiatry; 1986 Jul; 10(3-5):501-18. PubMed ID: 3541048
    [Abstract] [Full Text] [Related]

  • 4. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia.
    Chan-Palay V.
    J Comp Neurol; 1988 Jul 22; 273(4):543-57. PubMed ID: 2463283
    [Abstract] [Full Text] [Related]

  • 5. Impairment of basal forebrain cholinergic neurons associated with aging and long-term loss of ovarian function.
    Gibbs RB.
    Exp Neurol; 1998 Jun 22; 151(2):289-302. PubMed ID: 9628764
    [Abstract] [Full Text] [Related]

  • 6. Acetylcholine, aging, and Alzheimer's disease.
    Muir JL.
    Pharmacol Biochem Behav; 1997 Apr 22; 56(4):687-96. PubMed ID: 9130295
    [Abstract] [Full Text] [Related]

  • 7. Disturbances in neurotransmission processes in aging and age-related diseases.
    Ossowska K.
    Pol J Pharmacol; 1993 Apr 22; 45(2):109-31. PubMed ID: 8401765
    [Abstract] [Full Text] [Related]

  • 8. Dendritic reorganisation in the basal forebrain under degenerative conditions and its defects in Alzheimer's disease. III. The basal forebrain compared with other subcortical areas.
    Arendt T, Brückner MK, Bigl V, Marcova L.
    J Comp Neurol; 1995 Jan 09; 351(2):223-46. PubMed ID: 7699112
    [Abstract] [Full Text] [Related]

  • 9. The morphological basis of dementia in Parkinson's disease.
    Ball MJ.
    Can J Neurol Sci; 1984 Feb 09; 11(1 Suppl):180-4. PubMed ID: 6713315
    [Abstract] [Full Text] [Related]

  • 10. Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain.
    McGeer PL, McGeer EG, Suzuki J, Dolman CE, Nagai T.
    Neurology; 1984 Jun 09; 34(6):741-5. PubMed ID: 6539435
    [Abstract] [Full Text] [Related]

  • 11. The cholinergic system in Alzheimer's disease.
    Kása P, Rakonczay Z, Gulya K.
    Prog Neurobiol; 1997 Aug 09; 52(6):511-35. PubMed ID: 9316159
    [Abstract] [Full Text] [Related]

  • 12. Neuronal communication breakdown in neurotransmitter systems in Alzheimer's and Parkinson's dementias.
    Chan-Palay V.
    J Neurocytol; 1990 Oct 09; 19(5):802-6. PubMed ID: 1706418
    [No Abstract] [Full Text] [Related]

  • 13. Do raised brain aluminium levels in Alzheimer's dementia contribute to cholinergic neuronal deficits?
    King RG.
    Med Hypotheses; 1984 Jul 09; 14(3):301-6. PubMed ID: 6472159
    [Abstract] [Full Text] [Related]

  • 14. Detection of corticotropin-releasing hormone receptor 1 immunoreactivity in cholinergic, dopaminergic and noradrenergic neurons of the murine basal forebrain and brainstem nuclei--potential implication for arousal and attention.
    Sauvage M, Steckler T.
    Neuroscience; 2001 Jul 09; 104(3):643-52. PubMed ID: 11440798
    [Abstract] [Full Text] [Related]

  • 15. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease.
    Hall H, Reyes S, Landeck N, Bye C, Leanza G, Double K, Thompson L, Halliday G, Kirik D.
    Brain; 2014 Sep 09; 137(Pt 9):2493-508. PubMed ID: 25062696
    [Abstract] [Full Text] [Related]

  • 16. Alzheimer's disease: more than a 'cholinergic disorder' - evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia.
    Dringenberg HC.
    Behav Brain Res; 2000 Nov 09; 115(2):235-49. PubMed ID: 11000423
    [Abstract] [Full Text] [Related]

  • 17. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease.
    Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, Koeppe RA.
    Ann Neurol; 1996 Sep 09; 40(3):399-410. PubMed ID: 8797529
    [Abstract] [Full Text] [Related]

  • 18. Neurochemical basis of dementia in Parkinson's disease.
    Hornykiewicz O, Kish SJ.
    Can J Neurol Sci; 1984 Feb 09; 11(1 Suppl):185-90. PubMed ID: 6143610
    [Abstract] [Full Text] [Related]

  • 19. The toxicity of tumor necrosis factor-alpha upon cholinergic neurons within the nucleus basalis and the role of norepinephrine in the regulation of inflammation: implications for Alzheimer's disease.
    Wenk GL, McGann K, Hauss-Wegrzyniak B, Rosi S.
    Neuroscience; 2003 Feb 09; 121(3):719-29. PubMed ID: 14568031
    [Abstract] [Full Text] [Related]

  • 20. Reduced retrograde labelling with fluorescent tracer accompanies neuronal atrophy of basal forebrain cholinergic neurons in aged rats.
    De Lacalle S, Cooper JD, Svendsen CN, Dunnett SB, Sofroniew MV.
    Neuroscience; 1996 Nov 09; 75(1):19-27. PubMed ID: 8923519
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.